eligibility_summary
Includes: 18–70, histologically proven advanced/metastatic gastric or GEJ cancer after 1st‑line or post‑(neo)adjuvant, life ≥3 mo, ECOG 0–2, RECIST‑measurable lesion, adequate marrow/liver/renal, contraception. Excludes: other malignancy, severe allergy, uncontrolled infection, CNS mets, stroke/TIA/PE/untreated DVT or major CV events in ≤6 mo, uncontrolled HTN, QTc>480 ms, active bleeding/high‑risk GI issues, grade 3–4 diarrhea, serious comorbidity, illicit drugs, recent therapy (<14 d) or trial (<30 d), unresolved >grade 1 toxicity, pregnant, lactating, or planning.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: TCRx T cells—autologous CD8+ T cells genetically engineered (gene-edited, TCR-transduced) with a personalized, multi-target, tumor-specific TCR set, delivered as sequential IV infusions in an Early Phase 1, single-arm, dose-escalation study (≈1×10^7–1×10^9 cells/m^2). Mechanism of action: Redirects T-cell receptor specificity to recognize patient-specific tumor antigens/neoantigens presented by HLA class I on gastric/GEJ cancer cells, activating TCR signaling and CD8+ cytotoxic programs (cytokine release, perforin/granzyme-mediated killing), enabling recognition of intracellular antigens. Targets: Tumor cells presenting peptide–HLA class I complexes, key pathways include antigen processing/presentation (HLA-I), TCR signaling, and cytotoxic T-lymphocyte effector functions. Type: Personalized adoptive cellular immunotherapy (biologic).